On the Record · Ppd
Ppd acquisitions, on the record
The businesses Ppd bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Synarc, Inc.Word for word“On September 3, 2019, we acquired 100% of the issued and outstanding equity of Synarc, Inc. (“Synarc”), the global site network of Bioclinica, Inc., expanding its global footprint into China and Latin America and expanding its central nervous system offering in the United States.” 10-K for 2019 | acquisition | September 3, 2019 | — |
Medimix InternationalWord for word“On July 1, 2019, we acquired 100% of the issued and outstanding equity of Medimix International (“Medimix”), a global technology company that provides real-world evidence insights and information to the pharmaceutical, diagnostic and medical device industries.” 10-K for 2019 | acquisition | July 1, 2019 | — |
Optimal Research, LLCWord for word“On September 1, 2017, we acquired 100% of Optimal Research, LLC (“Optimal Research”), a dedicated clinical research site network with enhanced oncology enrollment capabilities.” 10-K for 2019 | acquisition | September 1, 2017 | — |
Evidera Holdings, Inc.Word for word“We acquired Synarc Inc. on September 3, 2019, Medimix International on July 1, 2019, Optimal Research, LLC on September 1, 2017, Evidera Holdings, Inc. on September 1, 2016, Synexus Clinical Research Topco Limited on May 31, 2016, CRA Intermediate Holdings, Inc. on May 12, 2015 and the clinical research division of SNBL, subsequently renamed PPD-SNBL, on April 1, 2015.” 10-K for 2019 | acquisition | September 1, 2016 | — |
Synexus Clinical Research Topco LimitedWord for word“We acquired Synarc Inc. on September 3, 2019, Medimix International on July 1, 2019, Optimal Research, LLC on September 1, 2017, Evidera Holdings, Inc. on September 1, 2016, Synexus Clinical Research Topco Limited on May 31, 2016, CRA Intermediate Holdings, Inc. on May 12, 2015 and the clinical research division of SNBL, subsequently renamed PPD-SNBL, on April 1, 2015.” 10-K for 2019 | acquisition | May 31, 2016 | — |
CRA Intermediate Holdings, Inc.Word for word“We acquired Synarc Inc. on September 3, 2019, Medimix International on July 1, 2019, Optimal Research, LLC on September 1, 2017, Evidera Holdings, Inc. on September 1, 2016, Synexus Clinical Research Topco Limited on May 31, 2016, CRA Intermediate Holdings, Inc. on May 12, 2015 and the clinical research division of SNBL, subsequently renamed PPD-SNBL, on April 1, 2015.” 10-K for 2019 | acquisition | May 12, 2015 | — |
clinical research division of SNBL (PPD-SNBL)Word for word“We acquired Synarc Inc. on September 3, 2019, Medimix International on July 1, 2019, Optimal Research, LLC on September 1, 2017, Evidera Holdings, Inc. on September 1, 2016, Synexus Clinical Research Topco Limited on May 31, 2016, CRA Intermediate Holdings, Inc. on May 12, 2015 and the clinical research division of SNBL, subsequently renamed PPD-SNBL, on April 1, 2015.” 10-K for 2019 | acquisition | April 1, 2015 | — |
Synarc, Inc. (the global site network of Bioclinica, Inc.)Word for word“On September 3, 2019, we acquired 100% of the issued and outstanding equity of Synarc, Inc. (“Synarc”), the global site network of Bioclinica, Inc., expanding our global footprint into China and Latin America and expanding our central nervous system offering in the United States.” 10-K for 2020 | acquisition | September 3, 2019 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2017-12-31 | $24.2 million | $0 | — |
| 2018-12-31 | −$224,000 | $8 million | — |
| 2019-12-31 | $74.2 million | $0 | $27.9 million |
| 2020-12-31 | −$321,000 | $0 | — |
Deal filings since 2016
- 2021-12-08 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2021-04-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-01-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-06-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-02-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Ppd’s annual reports (10-K for 2020, 10-K for 2019) and the financial data it files with the SEC, as of 2021-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.